Drugs / BonoFill-II
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03024008 | Jul 2017 → Mar 2027 expected | disease of bone structure | BonusBio Group Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02842619 | Jul 2016 → Jun 2024 | — | BonusBio Group Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BonoFill-II | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03024008 ↗ |
| Modality | Cell therapy | “BonoFill-II as a bone filler containing the patient's own (autologous) adipose (fat) tissue-derived cells” NCT02842619 ↗ |
| Route | Other | “BonoFill-II will be transplanted on the residual sub-antral bone.” NCT02842619 ↗ |